Novel targeted chemotherapeutics for gliobastoma

Active Project Grant Awarded Last action

Award ID
R44CA174129
Recipient
Awarding agency
Obligated
$8,723,055

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 94% complete
Originally
Funding
  • $7,354,819.00 Federal
  • $1,368,236.00 Non-federal
Place of performance
Los Altos, CA 94022, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $1,307,447 $0
Amendment $0 $0
Amendment $1,324,080 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,368,236 $0
Amendment $1,368,236 $1,368,236
Amendment $0 $0
Amendment Phase 1B/2A trial of QBS-72S for the treatment of newly diagnosed glioblastoma multiforme in patients with unmethylated mgmt promoters $0 $0
Amendment $968,230 $0
Original award $1,018,590 $0
Show all 17

Quick answers

Who received award R44CA174129?

R44CA174129 was awarded to Quadriga Biosciences, Inc. by National Cancer Institute (National Institutes of Health) on June 1, 2013.

How much is award R44CA174129 worth?

$8,723,055 has been obligated on R44CA174129: $7,354,819 in federal funding and $1,368,236 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award